1
|
Bonnot Ruget M, Moulin P, Pagan C, Cheillan D, Marmontel O, Raverot G, Benlian P, Di Filippo M. Diagnostic challenge between a frequent polygenic hypocholesterolemia and an unusual Smith Lemli Opitz syndrome related to bi-allelic DHCR7 mutations. Clin Chem Lab Med 2024; 0:cclm-2024-0162. [PMID: 38581293 DOI: 10.1515/cclm-2024-0162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 03/28/2024] [Indexed: 04/08/2024]
Affiliation(s)
- Mathilde Bonnot Ruget
- 26900 Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon , Lyon Cedex, France
| | - Philippe Moulin
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France
- 26900 Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE, Hospices Civils de Lyon , Bron Cedex, France
| | - Cécile Pagan
- 26900 Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon , Lyon Cedex, France
| | - David Cheillan
- 26900 Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon , Lyon Cedex, France
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Oriane Marmontel
- 26900 Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon , Lyon Cedex, France
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Gerald Raverot
- Lyon 1 University, Villeurbanne, France
- Endocrinology Department, 26900 Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon , Bron, France
- Inserm U1052, CNRS UMR5286, Cancer Research Center of Lyon, Lyon, France
| | - Pascale Benlian
- Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, UMR 1283 - EGID, Lille, France
| | - Mathilde Di Filippo
- 26900 Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon , Lyon Cedex, France
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| |
Collapse
|
2
|
Vasse J, Lassartesse A, Marmontel O, Charrière S, Bouveyron C, Marrié N, Moulin P, Di Filippo M. Assessment of three equations to calculate plasma LDL cholesterol concentration in fasting and non-fasting hypertriglyceridemic patients. Clin Chem Lab Med 2024; 62:270-279. [PMID: 37678263 DOI: 10.1515/cclm-2023-0360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Accepted: 08/25/2023] [Indexed: 09/09/2023]
Abstract
OBJECTIVES Low-density lipoprotein cholesterol (LDL-C) concentration was calculated for many years using the Friedewald equation, but those from Sampson and extended-Martin-Hopkins perform differently. Their accuracy in fasting hypertriglyceridemia and non-fasting state were compared and the clinical impact of implementing these equations on risk classification and on the setting of lipid treatment goals was assessed. METHODS Seven thousand six standard lipid profiles and LDL-C concentrations measured after ultracentrifugation (uLDL-C) were retrospectively included. uLDL-C were compared to calculated LDL-C in terms of correlation, root mean square error, residual error, mean absolute deviations and cardiovascular stratification. RESULTS In fasting state (n=5,826), Sampson equation was the most accurate, exhibited the highest percentage of residual error lower than 0.13 mmol/L (67 vs. 57 % and 63 % using Friedewald, or extended-Martin-Hopkins equations respectively) and the lowest misclassification rate. However, the superiority of this equation was less pronounced when triglyceride concentration (TG) <4.5 mmol/L were considered. In post-prandial state (n=1,180), extended-Martin-Hopkins was the most accurate equation, exhibited the highest percentage of residual error lower than 0.13 mmol/L (73 vs. 39 % and 57 % using Friedewald and Sampson equation respectively). Overall, the negative bias with Sampson equation may lead to undertreatment. Conversely, a positive bias was observed with extended Martin-Hopkins. CONCLUSIONS None of the equations tested are accurate when TG>4.52 mmol/L. When TG<4.52 mmol/L both Sampson and Martin-Hopkins equations performed better than Friedewald. The switch to one or the other should take in account their limitations, their ease of implementation into the lab software and the proportion of non-fasting patients.
Collapse
Affiliation(s)
- Joséphine Vasse
- UF Dyslipidémies, Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon Bron, France
| | - Audrey Lassartesse
- UF Dyslipidémies, Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon Bron, France
| | - Oriane Marmontel
- UF Dyslipidémies, Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon Bron, France
- CarMen Laboratory, INSERM, INRA, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Sybil Charrière
- CarMen Laboratory, INSERM, INRA, Université Claude Bernard Lyon 1, Pierre-Bénite, France
- Hospices Civils de Lyon, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Bron, France
| | - Caroline Bouveyron
- UF Dyslipidémies, Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon Bron, France
| | - Nathanaël Marrié
- UF Dyslipidémies, Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon Bron, France
| | - Philippe Moulin
- CarMen Laboratory, INSERM, INRA, Université Claude Bernard Lyon 1, Pierre-Bénite, France
- Hospices Civils de Lyon, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Bron, France
| | - Mathilde Di Filippo
- UF Dyslipidémies, Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon Bron, France
- CarMen Laboratory, INSERM, INRA, Université Claude Bernard Lyon 1, Pierre-Bénite, France
- Hospices Civils de Lyon, Groupement Hospitalier Est, Centre de Biologie et de Pathologies Est (Aile A3), Bron Cedex, France
| |
Collapse
|
3
|
Henry Z, Janin A, Nony S, Marmontel O, Cariou B, Marrec M, Caussy C, Charrière S, Moulin P, Rieusset J, Perros F, Di Filippo M. Interest of minigene splicing reporter assay in familial hypobetalipoproteinemia genetic diagnosis: the example of the missense mutation APOB c.1468C>T. Clin Chem Lab Med 2023; 61:e259-e262. [PMID: 37309596 DOI: 10.1515/cclm-2023-0330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 06/02/2023] [Indexed: 06/14/2023]
Affiliation(s)
- Zoé Henry
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Alexandre Janin
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
- CNRS UMR5261, INSERM U1315, Institut NeuroMyoGène, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Séverine Nony
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
| | - Oriane Marmontel
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Bertrand Cariou
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du Thorax, Nantes, France
| | - Marie Marrec
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du Thorax, Nantes, France
| | - Cyrielle Caussy
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
- Hôpital Lyon Sud, Département Endocrinologie, Diabète et Nutrition, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Sybil Charrière
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Philippe Moulin
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Jennifer Rieusset
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Frédéric Perros
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| | - Mathilde Di Filippo
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
- CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon 1, Pierre-Bénite, France
| |
Collapse
|
4
|
Nocturne G, Marmontel O, di Filippo M, Chretien P, Krzysiek R, Lifermann F, Rahal N, Belkhir R, Moulin P, Mariette X. Efficacy of daratumumab in refractory primary Sjögren disease. RMD Open 2023; 9:e003464. [PMID: 37730313 PMCID: PMC10510860 DOI: 10.1136/rmdopen-2023-003464] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/07/2023] [Indexed: 09/22/2023] Open
Affiliation(s)
- Gaetane Nocturne
- Rheumatology Department, Hôpital Bicêtre, Le Kremlin-Bicetre, France
- INSERM UMR 1184, Le Kremlin-Bicêtre, France
| | - Oriane Marmontel
- Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, F-69677, Lyon Cedex, France, Lyon, France
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Mathilde di Filippo
- Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, F-69677, Lyon Cedex, France, Lyon, France
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Pascale Chretien
- Laboratoire d'Immunologie, Hopital Bicetre, Le Kremlin-Bicetre, France
| | - Roman Krzysiek
- Laboratoire d'Immunologie, Hopital Bicetre, Le Kremlin-Bicetre, France
| | | | - Nawal Rahal
- Rheumatology Department, Hôpital Bicêtre, Le Kremlin-Bicetre, France
| | - Rakiba Belkhir
- Rheumatology Department, Hôpital Bicêtre, Le Kremlin-Bicetre, France
| | - Philippe Moulin
- Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, F-69677, Lyon Cedex, France, Lyon, France
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Xavier Mariette
- Rheumatology Department, Hôpital Bicêtre, Le Kremlin-Bicetre, France
- INSERM UMR 1184, Le Kremlin-Bicêtre, France
| |
Collapse
|
5
|
Marmontel O, Abou-Khalil Y, Bluteau O, Cariou B, Carreau V, Charrière S, Divry E, Gallo A, Moulin P, Paillard F, Peretti N, Rabès JP, Varret M, Carrié A, Di Filippo M. Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 2023. [PMID: 37128917 DOI: 10.1161/atvbaha.123.319146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
BACKGROUND Autosomal dominant hypercholesterolemia (ADH) is due to deleterious variants in LDLR, APOB, or PCSK9 genes. Double heterozygote for these genes induces a more severe phenotype. More recently, a new causative variant of heterozygous ADH was identified in APOE. Here we study the phenotype of 21 adult patients, double heterozygotes for rare LDLR and rare APOE variants (LDLR+APOE) in a national wide French cohort. METHODS LDLR, APOB, PCSK9, and APOE genes were sequenced in 5743 probands addressed for ADH genotyping. The lipid profile and occurrence of premature atherosclerotic cardiovascular diseases were compared between the LDLR+APOE carriers (n=21) and the carriers of the same LDLR causative variants alone (n=22). RESULTS The prevalence of LDLR+APOE carriers in this French ADH cohort is 0.4%. Overall, LDL (low-density lipoprotein)-cholesterol concentrations were 23% higher in LDLR+APOE patients than in LDLR patients (9.14±2.51 versus 7.43±1.59 mmol/L, P=0.0221). When only deleterious or probably deleterious variants were considered, the LDL-cholesterol concentrations were 46% higher in LDLR+APOE carriers than in LDLR carriers (10.83±3.45 versus 7.43±1.59 mmol/L, P=0.0270). Two patients exhibited a homozygous familial hypercholesterolemia phenotype (LDL-cholesterol >13 mmol/L). Premature atherosclerotic cardiovascular disease was more common in LDLR+APOE patients than in LDLR carriers (70% versus 30%, P=0.026). CONCLUSIONS Although an incomplete penetrance should be taken into account for APOE variant classification, these results suggest an additive effect of deleterious APOE variants on ADH phenotype highlighting the relevance of APOE sequencing.
Collapse
Affiliation(s)
- Oriane Marmontel
- Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-Sites, Hospices Civils de Lyon, France. (O.M., E.D., M.D.F.)
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (O.M., S.C., P.M., N.P., M.D.F.)
| | - Yara Abou-Khalil
- Université Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, Paris, France (Y.A.-K., J.-P.R., M.V.)
- Laboratory of Biochemistry and Molecular Therapeutics (LBTM), Faculty of Pharmacy, Pôle Technologie- Santé (PTS), Saint-Joseph University, Beirut, Lebanon (Y.A.-K.)
| | - Olivier Bluteau
- INSERM UMRS 1166 - ICAN, Faculty of Medicine Pitie-Salpétrière, Sorbonne University, Paris, France (O.B., A.C.)
- Service de Biochimie Endocrinienne et Oncologique, AP-HP Sorbonne Université Pitié Salpêtrière, Paris, France (O.B., A.C.)
| | - Bertrand Cariou
- Nantes Université, CHU NANTES, CNRS, INSERM, l'institut du Thorax, France (B.C.)
| | - Valérie Carreau
- Endocrinology and Metabolism Department, Human Research Nutrition Center, Pitié-Salpêtrière Hospital, AP-HP, Paris, France (V.C., A.G., P.M.)
| | - Sybil Charrière
- Fédération d'Endocrinologie, Maladies Métaboliques, Diabète et Nutrition, GHE, Hospices Civils de Lyon, France. (S.C.)
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (O.M., S.C., P.M., N.P., M.D.F.)
| | - Eleonore Divry
- Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-Sites, Hospices Civils de Lyon, France. (O.M., E.D., M.D.F.)
| | - Antonio Gallo
- Endocrinology and Metabolism Department, Human Research Nutrition Center, Pitié-Salpêtrière Hospital, AP-HP, Paris, France (V.C., A.G., P.M.)
| | - Philippe Moulin
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (O.M., S.C., P.M., N.P., M.D.F.)
- Endocrinology and Metabolism Department, Human Research Nutrition Center, Pitié-Salpêtrière Hospital, AP-HP, Paris, France (V.C., A.G., P.M.)
| | - François Paillard
- Cardiologie et Maladies vasculaires, Centre Hospitalier de Rennes, France (F.P.)
| | - Noel Peretti
- Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, HFME, Hospices Civils de Lyon, France. (N.P.)
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (O.M., S.C., P.M., N.P., M.D.F.)
| | - Jean-Pierre Rabès
- Université Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, Paris, France (Y.A.-K., J.-P.R., M.V.)
- Laboratoire de Biochimie et Génétique Moléculaire, Hôpital Ambroise Paré, AP-HP. Université Paris Saclay, Boulogne-Billancourt, France (J.-P.R.)
- UVSQ, UFR Simone Veil- Santé, Montigny-Le-Bretonneux, France (J.-P.R.)
| | - Mathilde Varret
- Université Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, Paris, France (Y.A.-K., J.-P.R., M.V.)
| | - Alain Carrié
- INSERM UMRS 1166 - ICAN, Faculty of Medicine Pitie-Salpétrière, Sorbonne University, Paris, France (O.B., A.C.)
- Service de Biochimie Endocrinienne et Oncologique, AP-HP Sorbonne Université Pitié Salpêtrière, Paris, France (O.B., A.C.)
| | - Mathilde Di Filippo
- Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-Sites, Hospices Civils de Lyon, France. (O.M., E.D., M.D.F.)
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (O.M., S.C., P.M., N.P., M.D.F.)
| |
Collapse
|
6
|
Monneret D, Moreau A, Chirica C, Guergour D, Richet C, Desmurs L, Colognac S, Frugier A, Chévrier M, Marmontel O, Bonnefont-Rousselot D, Gonzalo P, Rodriguez-Lafrasse C, Cartier R. Non-linearity in lipase assays: A multicentric comparison on different analysers. Clin Biochem 2023; 114:63-66. [PMID: 36773631 DOI: 10.1016/j.clinbiochem.2023.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/21/2023] [Accepted: 02/08/2023] [Indexed: 02/13/2023]
Abstract
OBJECTIVES Non-linearity in lipase assays and the ensuing gaps in results distribution have been described on Roche analysers, but have yet to be studied on other analysers. DESIGN AND METHODS Eighteen lithium-heparinized plasma pools of lipase activities decreasing from 1700 to <4 U/L were prepared for multicentric evaluation on several analysers. Non-linearity was modelled as the difference between the polynomial regression of lipase activities depending on relative dilutions over the primary measuring range, and the linear regression of the same variables above the manufacturer's limit of linearity (MLL). Gaps in lipase distribution resulting from non-linearity were graphically evidenced through histograms. Upper limits of gaps were calculated, which are lipase activities where non-linearity biases no longer impact the diluted lipase results. RESULTS MLLs and lipase (U/L) calculated at MLL (%biases versus MLL) were respectively: 1200 and 1124 (-6.3%) on the Architect C16000 (Abbott); 300 and 248 (-17.3%) on the Cobas c503 (Roche); 1500 and 1458 (-2.8%) on the Dimension Vista (Siemens); and 700 and 659 (-5.9%) on the Atellica CH930 (Siemens). Using Sentinel Lipase reagents on Abbott analysers, these measurements were respectively: 300 and 294 (-2.0%) on the Architect C16000, and 300 and 298 (-0.7%) on the Alinity. Setting Randox Lipase reagents on the Alinity, MLL and lipase at MLL were 953 and 776 (-18.6%), respectively. CONCLUSIONS Considering the desirable (±14.2 %) and optimal (±7.1 %) allowable total error for lipase (EFLM/EuBIVAS), biases at manufacturer's limit of linearity were acceptable, except for Roche Cobas c503 method and Randox method on Abbott Alinity.
Collapse
Affiliation(s)
- Denis Monneret
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France.
| | - Amélie Moreau
- Service de Biochimie, CHU Saint-Etienne, F-42000 Saint-Etienne, France
| | - Carole Chirica
- Unité de Biochimie Immunoanalyse, Service de Biochimie Biologie Moléculaire et Toxicologie Environnementale, Institut de Biologie et Pathologie, CHU Grenoble, Université Grenoble Alpes, F-38000 Grenoble, France
| | - Dorra Guergour
- Unité de Biochimie Immunoanalyse, Service de Biochimie Biologie Moléculaire et Toxicologie Environnementale, Institut de Biologie et Pathologie, CHU Grenoble, Université Grenoble Alpes, F-38000 Grenoble, France
| | - Caroline Richet
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Laurent Desmurs
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Sylvie Colognac
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Audrey Frugier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Marc Chévrier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Oriane Marmontel
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Dominique Bonnefont-Rousselot
- Service de Biochimie Métabolique, AP-HP, Sorbonne Université, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, F-75000 Paris, France; Université Paris Cité, CNRS, INSERM, UTCBS, F-75006 Paris, France
| | - Philippe Gonzalo
- Service de Biochimie, CHU Saint-Etienne, F-42000 Saint-Etienne, France
| | - Claire Rodriguez-Lafrasse
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Régine Cartier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| |
Collapse
|
7
|
Smati S, Di Filippo M, Marmontel O, Airault S, Scharbarg E, Bienfait F, Paillard A, Collin-Chavagnac D, Moulin P, Cariou B. Rémission d’une hypertriglycéridémie auto-immune sévère après traitement immunosuppresseur. Annales d'Endocrinologie 2023. [DOI: 10.1016/j.ando.2022.12.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
|
8
|
Lefèvre CR, Gibert C, Maucorps L, Vasse J, Michel M, Chupin M, Zhao F, Desmurs L, Collet N, Di Filippo M, Cartier R, Monneret D, Marmontel O. Pseudohyponatremia: interference of hyperglycemia on indirect potentiometry. Clin Chem Lab Med 2023; 61:e25-e28. [PMID: 36282968 DOI: 10.1515/cclm-2022-0766] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 10/14/2022] [Indexed: 12/15/2022]
Affiliation(s)
- Charles R Lefèvre
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
- Laboratoire de Biochimie-Toxicologie, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
| | - Charles Gibert
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Laure Maucorps
- Laboratoire de Biochimie-Toxicologie, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
| | - Joséphine Vasse
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Marie Michel
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Marine Chupin
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Fanny Zhao
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Laurent Desmurs
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Nicolas Collet
- Laboratoire de Biochimie-Toxicologie, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
| | - Mathilde Di Filippo
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Régine Cartier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Denis Monneret
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| | - Oriane Marmontel
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), Lyon, France
| |
Collapse
|
9
|
Vanhoye X, Bardel C, Rimbert A, Moulin P, Rollat-Farnier PA, Muntaner M, Marmontel O, Dumont S, Charrière S, Cornélis F, Ducluzeau PH, Fonteille A, Nobecourt E, Peretti N, Schillo F, Wargny M, Cariou B, Meirhaeghe A, Di Filippo M. A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res 2022; 255:119-127. [PMID: 36528340 DOI: 10.1016/j.trsl.2022.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 11/14/2022] [Accepted: 12/09/2022] [Indexed: 12/16/2022]
Abstract
Genetic diagnosis of familial hypercholesterolemia (FH) remains unexplained in 30 to 70% of patients after exclusion of monogenic disease. There is now a growing evidence that a polygenic burden significantly modulates LDL-cholesterol (LDL-c) concentrations. Several LDL-c polygenic risk scores (PRS) have been set up. However, the balance between their diagnosis performance and their practical use in routine practice is not clearly established. Consequently, we set up new PRS based on our routine panel for sequencing and compared their diagnostic performance with previously-published PRS. After a meta-analysis, four new PRS including 165 to 1633 SNP were setup using different softwares. They were established using two French control cohorts (MONA LISA n=1082 and FranceGenRef n=856). Then the explained LDL-c variance and the ability of each PRS to discriminate monogenic negative FH patients (M-) versus healthy controls were compared with 4 previously-described PRS in 785 unrelated FH patients. Between all PRS, the 165-SNP PRS developed with PLINK showed the best LDL-c explained variance (adjusted R²=0.19) and the best diagnosis abilities (AUROC=0.77, 95%CI=0.74-0.79): it significantly outperformed all the previously-published PRS (p<1 × 10-4). By using a cut-off at the 75th percentile, 61% of M- patients exhibited a polygenic hypercholesterolemia with the 165-SNP PRS versus 48% with the previously published 12-SNP PRS (p =3.3 × 10-6). These results were replicated using the UK biobank. This new 165-SNP PRS, usable in routine diagnosis, exhibits better diagnosis abilities for a polygenic hypercholesterolemia diagnosis. It would be a valuable tool to optimize referral for whole genome sequencing.
Collapse
Affiliation(s)
- Xavier Vanhoye
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
| | - Claire Bardel
- Laboratoire de Biométrie et Biologie Evolutive UMR 5558, Université de Lyon, Université Lyon 1, CNRS, Villeurbanne, France; Plateforme de séquençage NGS HCL, Cellule bio-informatique, Hospices Civils de Lyon, Lyon, France
| | - Antoine Rimbert
- Institut du thorax, Nantes Université, CHU Nantes, CNRS, Inserm, Nantes, France
| | - Philippe Moulin
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France; Laboratoire CarMen, INSERM U1060, INRAE U1397, Oullins, France
| | | | - Manon Muntaner
- Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, INSERM, Centre Hospitalo-Universitaire Lille, Lille, France
| | - Oriane Marmontel
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France; Laboratoire CarMen, INSERM U1060, INRAE U1397, Oullins, France
| | - Sabrina Dumont
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France
| | - Sybil Charrière
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France; Laboratoire CarMen, INSERM U1060, INRAE U1397, Oullins, France
| | - François Cornélis
- Génétique - Oncogénétique Adulte - Prévention, Centre Hospitalo-Universitaire et Université Clermont-Auvergne, Clermont-Ferrand, France
| | - Pierre Henri Ducluzeau
- Unité d'endocrinologie, Centre Hospitalo-Universitaire Bretonneau, Université de Tours, Tours, France
| | - Annie Fonteille
- Infectiologie, Médecine Interne, Médecine des voyages, Centre Hospitalier d'Annecy Genevois, Epagny Metz-Tessy, Annecy, France
| | - Estelle Nobecourt
- Service d'Endocrinologie, Diabète et Nutrition et Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) U1410 INSERM, Centre Hospitalo-Universitaire de la Réunion, Saint-Pierre, La Réunion, France
| | - Noël Peretti
- Laboratoire CarMen, INSERM U1060, INRAE U1397, Oullins, France; Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE, Hospices Civils de Lyon, Lyon, France
| | - Franck Schillo
- Service de Diabétologie-Endocrinologie-Nutrition, Centre Hospitalo-Universitaire Jean Minjoz Besançon France
| | - Matthieu Wargny
- Institut du thorax, Nantes Université, CHU Nantes, CNRS, Inserm, Nantes, France
| | - Bertrand Cariou
- Institut du thorax, Nantes Université, CHU Nantes, CNRS, Inserm, Nantes, France
| | - Aline Meirhaeghe
- Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, INSERM, Centre Hospitalo-Universitaire Lille, Lille, France
| | - Mathilde Di Filippo
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, Bron, France; Laboratoire CarMen, INSERM U1060, INRAE U1397, Oullins, France.
| |
Collapse
|
10
|
Henry Z, Marmontel O, Balaire L, Marsot C, Di Filippo M, Moulin P, Charriere S. Comparison of coronary artery calcium score and its determinants in patients with familial combined hyperlipidemia and type 2 diabetes, in primary cardiovascular prevention. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Vanhoye X, Janin A, Caillaud A, Rimbert A, Venet F, Gosset M, Dijk W, Marmontel O, Nony S, Chatelain C, Lindenbaum P, Cariou B, Moulin P, Di Filippo M. Leu351Arg in apoB, a new missense variant causing familial hypobetalipoproteinemia. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Vanhoye X, Janin A, Caillaud A, Rimbert A, Venet F, Gossez M, Dijk W, Marmontel O, Nony S, Chatelain C, Durand C, Lindenbaum P, Rieusset J, Cariou B, Moulin P, Di Filippo M. APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants. Int J Mol Sci 2022; 23:ijms23084281. [PMID: 35457099 PMCID: PMC9030618 DOI: 10.3390/ijms23084281] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 04/04/2022] [Accepted: 04/11/2022] [Indexed: 02/01/2023] Open
Abstract
Hypobetalipoproteinemia is characterized by LDL-cholesterol and apolipoprotein B (apoB) plasma levels below the fifth percentile for age and sex. Familial hypobetalipoproteinemia (FHBL) is mostly caused by premature termination codons in the APOB gene, a condition associated with fatty liver and steatohepatitis. Nevertheless, many families with a FHBL phenotype carry APOB missense variants of uncertain significance (VUS). We here aimed to develop a proof-of-principle experiment to assess the pathogenicity of VUS using the genome editing of human liver cells. We identified a novel heterozygous APOB-VUS (p.Leu351Arg), in a FHBL family. We generated APOB knock-out (KO) and APOB-p.Leu351Arg knock-in Huh7 cells using CRISPR-Cas9 technology and studied the APOB expression, synthesis and secretion by digital droplet PCR and ELISA quantification. The APOB expression was decreased by 70% in the heterozygous APOB-KO cells and almost abolished in the homozygous-KO cells, with a consistent decrease in apoB production and secretion. The APOB-p.Leu351Arg homozygous cells presented with a 40% decreased APOB expression and undetectable apoB levels in cellular extracts and supernatant. Thus, the p.Leu351Arg affected the apoB secretion, which led us to classify this new variant as likely pathogenic and to set up a hepatic follow-up in this family. Therefore, the functional assessment of APOB-missense variants, using gene-editing technologies, will lead to improvements in the molecular diagnosis of FHBL and the personalized follow-up of these patients.
Collapse
Affiliation(s)
- Xavier Vanhoye
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, F-69677 Bron, France; (X.V.); (A.J.); (O.M.); (S.N.); (C.C.)
| | - Alexandre Janin
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, F-69677 Bron, France; (X.V.); (A.J.); (O.M.); (S.N.); (C.C.)
- Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Université Claude Bernard Lyon 1, Université de Lyon, F-69008 Lyon, France
| | - Amandine Caillaud
- Institut du Thorax, Nantes Université, CHU Nantes, CNRS, INSERM, F-44000 Nantes, France; (A.C.); (B.C.)
| | - Antoine Rimbert
- Institut du Thorax, Nantes Université, CNRS, INSERM, F-44000 Nantes, France; (A.R.); (W.D.); (P.L.)
| | - Fabienne Venet
- Laboratoire d’Immunologie, Edouard Herriot Hospital, Hospices Civils de Lyon, F-69437 Lyon, France; (F.V.); (M.G.)
- Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, F-69364 Lyon, France
| | - Morgane Gossez
- Laboratoire d’Immunologie, Edouard Herriot Hospital, Hospices Civils de Lyon, F-69437 Lyon, France; (F.V.); (M.G.)
- Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, F-69364 Lyon, France
| | - Wieneke Dijk
- Institut du Thorax, Nantes Université, CNRS, INSERM, F-44000 Nantes, France; (A.R.); (W.D.); (P.L.)
| | - Oriane Marmontel
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, F-69677 Bron, France; (X.V.); (A.J.); (O.M.); (S.N.); (C.C.)
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, F-69364 Lyon, France; (C.D.); (J.R.); (P.M.)
| | - Séverine Nony
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, F-69677 Bron, France; (X.V.); (A.J.); (O.M.); (S.N.); (C.C.)
| | - Charlotte Chatelain
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, F-69677 Bron, France; (X.V.); (A.J.); (O.M.); (S.N.); (C.C.)
| | - Christine Durand
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, F-69364 Lyon, France; (C.D.); (J.R.); (P.M.)
| | - Pierre Lindenbaum
- Institut du Thorax, Nantes Université, CNRS, INSERM, F-44000 Nantes, France; (A.R.); (W.D.); (P.L.)
| | - Jennifer Rieusset
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, F-69364 Lyon, France; (C.D.); (J.R.); (P.M.)
| | - Bertrand Cariou
- Institut du Thorax, Nantes Université, CHU Nantes, CNRS, INSERM, F-44000 Nantes, France; (A.C.); (B.C.)
| | - Philippe Moulin
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, F-69364 Lyon, France; (C.D.); (J.R.); (P.M.)
- Fédération d’Endocrinologie, Maladies Métaboliques, Diabète et Nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, F-69677 Bron, France
| | - Mathilde Di Filippo
- Service de Biochimie et de Biologie Moléculaire, Laboratoire de Biologie Médicale MultiSites, Hospices Civils de Lyon, F-69677 Bron, France; (X.V.); (A.J.); (O.M.); (S.N.); (C.C.)
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, F-69364 Lyon, France; (C.D.); (J.R.); (P.M.)
- Correspondence: ; Tel.: +33-04-7211-8994
| |
Collapse
|
13
|
Vanhoye X, Rimbert A, Moulin P, Bardel C, Rollat-Farnier PA, Muntaner M, Marmontel O, Peretti N, Fournier C, Pichelin M, Charrière S, Divry E, Chatelain C, Meirhaeghe A, Cariou B, Di Filippo M. Evaluation of new polygenic risk scores in the diagnosis of familial hypobetalipoproteinemia. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Bouzehouane N, Charrière S, Moret M, Groisne L, Villar-Fimbel S, Marmontel O, Di Filippo M, Collin-Chavagnac D, Marcais C, Moulin P. Kinetics of triglyceride decrease during hospitalisation for major hyperchylomicronemia in multifactorial chylomicronemia syndrome. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Vanhoye X, Janin A, Bachour N, Petot-Rosa S, Marmontel O, Nony S, Charrière S, Peretti N, Moulin P, Di Filippo M. Impact of APOB missense variations on apolipoprotein B secretion: A CRISPR-cas9 model. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Decourt C, Janin A, Moindrot M, Chatron N, Nony S, Muntaner M, Dumont S, Divry E, Dauchet L, Meirhaeghe A, Marmontel O, Bardel C, Charrière S, Cariou B, Moulin P, Di Filippo M. PCSK9 post-transcriptional regulation: Role of a 3′UTR microRNA-binding site variant in linkage disequilibrium with c.1420G. Atherosclerosis 2020; 314:63-70. [DOI: 10.1016/j.atherosclerosis.2020.10.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Revised: 09/21/2020] [Accepted: 10/07/2020] [Indexed: 02/05/2023]
|
17
|
Rimbert A, Vanhoye X, Coulibaly D, Marrec M, Pichelin M, Charrière S, Peretti N, Valéro R, Wargny M, Carrié A, Lindenbaum P, Deleuze JF, Genin E, Redon R, Rollat-Farnier PA, Goxe D, Degraef G, Marmontel O, Divry E, Bigot-Corbel E, Moulin P, Cariou B, Di Filippo M. Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2020; 41:e63-e71. [PMID: 33207932 DOI: 10.1161/atvbaha.120.315491] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
OBJECTIVE Primary hypobetalipoproteinemia is characterized by LDL-C (low-density lipoprotein cholesterol) concentrations below the fifth percentile. Primary hypobetalipoproteinemia mostly results from heterozygous mutations in the APOB (apolipoprotein B) and PCSK9 genes, and a polygenic origin is hypothesized in the remaining cases. Hypobetalipoproteinemia patients present an increased risk of nonalcoholic fatty liver disease and steatohepatitis. Here, we compared hepatic alterations between monogenic, polygenic, and primary hypobetalipoproteinemia of unknown cause. Approach and Results: Targeted next-generation sequencing was performed in a cohort of 111 patients with hypobetalipoproteinemia to assess monogenic and polygenic origins using an LDL-C-dedicated polygenic risk score. Forty patients (36%) had monogenic hypobetalipoproteinemia, 38 (34%) had polygenic hypobetalipoproteinemia, and 33 subjects (30%) had hypobetalipoproteinemia from an unknown cause. Patients with monogenic hypobetalipoproteinemia had lower LDL-C and apolipoprotein B plasma levels compared with those with polygenic hypobetalipoproteinemia. Liver function was assessed by hepatic ultrasonography and liver enzymes levels. Fifty-nine percent of patients with primary hypobetalipoproteinemia presented with liver steatosis, whereas 21% had increased alanine aminotransferase suggestive of liver injury. Monogenic hypobetalipoproteinemia was also associated with an increased prevalence of liver steatosis (81% versus 29%, P<0.001) and liver injury (47% versus 0%) compared with polygenic hypobetalipoproteinemia. CONCLUSIONS This study highlights the importance of genetic diagnosis in the clinical care of primary hypobetalipoproteinemia patients. It shows for the first time that a polygenic origin of hypobetalipoproteinemia is associated with a lower risk of liver steatosis and liver injury versus monogenic hypobetalipoproteinemia. Thus, polygenic risk score is a useful tool to establish a more personalized follow-up of primary hypobetalipoproteinemia patients.
Collapse
Affiliation(s)
- Antoine Rimbert
- Université de Nantes, CNRS, INSERM, l'institut du thorax, France (A.R., M.P., M.W., P.L., R.R., B.C.)
| | - Xavier Vanhoye
- Hospices Civils de Lyon, UF Dyslipidémies Service de Biochimie et de Biologie Moléculaire Grand Est, Bron, France (X.V., D.C., O.M., E.D., M.D.F.)
| | - Dramane Coulibaly
- Hospices Civils de Lyon, UF Dyslipidémies Service de Biochimie et de Biologie Moléculaire Grand Est, Bron, France (X.V., D.C., O.M., E.D., M.D.F.)
| | - Marie Marrec
- L'institut du thorax, CHU NANTES, CIC INSERM 1413, France (M.M., M.P., M.W., B.C.)
| | - Matthieu Pichelin
- L'institut du thorax, CHU NANTES, CIC INSERM 1413, France (M.M., M.P., M.W., B.C.)
| | - Sybil Charrière
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (S.C., N.P., O.M., P.M., M.D.F.).,Hospices Civils de Lyon, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Bron, France (S.C., P.M.)
| | - Noël Peretti
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (S.C., N.P., O.M., P.M., M.D.F.).,Hospices Civils de Lyon, Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, HFME, Bron, France (N.P.)
| | - René Valéro
- Aix Marseille Univ, APHM, INSERM, INRAE, C2VN, University Hospital La Conception, Department of Nutrition, Metabolic Diseases and Endocrinology, Marseille, France (R.V.)
| | - Matthieu Wargny
- Université de Nantes, CNRS, INSERM, l'institut du thorax, France (A.R., M.P., M.W., P.L., R.R., B.C.).,L'institut du thorax, CHU NANTES, CIC INSERM 1413, France (M.M., M.P., M.W., B.C.)
| | - Alain Carrié
- Sorbonne Universite, Inserm UMR_S116, Institute of Cardiometabolism and Nutrition (ICAN), Hopital Pitie-Salpetriere 75651 Paris, France (A.C.).,UF de génétique de l'Obésité et des Dyslipidémies, Laboratoire de Biochimie Endocrinienne et Oncologique, APHP, Sorbonne Université, Hôpital de la Pitié-salpêtrière, Paris, France (A.C.)
| | - Pierre Lindenbaum
- Université de Nantes, CNRS, INSERM, l'institut du thorax, France (A.R., M.P., M.W., P.L., R.R., B.C.)
| | - Jean-François Deleuze
- Centre National de Recherche en Génomique Humaine, Institut de Génomique, CEA, Evry, France (J.-F.D.)
| | - Emmanuelle Genin
- Inserm, Univ Brest, EFS, CHU Brest, UMR 1078, GGB, France (E.G.)
| | - Richard Redon
- Université de Nantes, CNRS, INSERM, l'institut du thorax, France (A.R., M.P., M.W., P.L., R.R., B.C.)
| | | | - Didier Goxe
- CPAM, Centre d'examens de santé de la CPAM de la Vendée, La Roche-sur-Yon, France (D.G.)
| | | | - Oriane Marmontel
- Hospices Civils de Lyon, UF Dyslipidémies Service de Biochimie et de Biologie Moléculaire Grand Est, Bron, France (X.V., D.C., O.M., E.D., M.D.F.).,CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (S.C., N.P., O.M., P.M., M.D.F.)
| | - Eléonore Divry
- Hospices Civils de Lyon, UF Dyslipidémies Service de Biochimie et de Biologie Moléculaire Grand Est, Bron, France (X.V., D.C., O.M., E.D., M.D.F.)
| | - Edith Bigot-Corbel
- Laboratoire de Biochimie, CHU de Nantes, Hôpital G et R Laënnec, Bd Jacques Monod, Saint-Herblain (E.B.-C.)
| | - Philippe Moulin
- CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (S.C., N.P., O.M., P.M., M.D.F.).,Hospices Civils de Lyon, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Bron, France (S.C., P.M.)
| | - Bertrand Cariou
- Université de Nantes, CNRS, INSERM, l'institut du thorax, France (A.R., M.P., M.W., P.L., R.R., B.C.).,L'institut du thorax, CHU NANTES, CIC INSERM 1413, France (M.M., M.P., M.W., B.C.)
| | - Mathilde Di Filippo
- Hospices Civils de Lyon, UF Dyslipidémies Service de Biochimie et de Biologie Moléculaire Grand Est, Bron, France (X.V., D.C., O.M., E.D., M.D.F.).,CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France (S.C., N.P., O.M., P.M., M.D.F.)
| |
Collapse
|
18
|
Serveaux Dancer M, Marmontel O, Wozny AS, Marcais C, Mahl M, Dumont S, Simonet T, Moulin P, Di Filippo M, Charrière S. Involvement of a homozygous exon 6 deletion of LMF1 gene in intermittent severe hypertriglyceridemia. J Clin Lipidol 2020; 14:756-761. [PMID: 33039347 DOI: 10.1016/j.jacl.2020.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 09/10/2020] [Accepted: 09/14/2020] [Indexed: 11/16/2022]
Abstract
Severe hypertriglyceridemia (HTG), characterized by triglycerides (TG) permanently over 10 mmol/L, may correspond to familial chylomicronemia syndrome (FCS), a rare disorder. However, hypertriglyceridemic patients more often present multifactorial chylomicronemia syndrome (MCS), characterized by highly variable TG. A few nonsense variants of LMF1 gene were reported in literature in FCS patients. In this study, we described a woman with an intermittent severe HTG. NGS analysis and the sequencing of a long range PCR product revealed a homozygous deletion of 6507 base pairs in LMF1 gene, c.730-1528_898-3417del, removing exon 6, predicted to create an in-frame deletion of 56 amino acids, p.(Thr244_Gln299del). Despite an exon 6 homozygous deletion of LMF1, the patient's highly variable lipid phenotype was suggestive of MCS diagnosis.
Collapse
Affiliation(s)
- Marine Serveaux Dancer
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie Moléculaire et Métabolique, Pierre-Bénite Cedex, France
| | - Oriane Marmontel
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Oullins Cedex, France; Hospices Civils de Lyon, Groupement Hospitalier Est, Service de Biochimie et Biologie Moléculaire Grand Est, Bron Cedex, France
| | - Anne-Sophie Wozny
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie Moléculaire et Métabolique, Pierre-Bénite Cedex, France
| | - Christophe Marcais
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie Moléculaire et Métabolique, Pierre-Bénite Cedex, France; INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Oullins Cedex, France
| | - Muriel Mahl
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie Moléculaire et Métabolique, Pierre-Bénite Cedex, France
| | - Sabrina Dumont
- Hospices Civils de Lyon, Groupement Hospitalier Est, Service de Biochimie et Biologie Moléculaire Grand Est, Bron Cedex, France
| | - Thomas Simonet
- Hospices Civils de Lyon, Cellule BioInformatique, Bron Cedex, France
| | - Philippe Moulin
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Oullins Cedex, France; Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'endocrinologie, Maladies Métaboliques, Diabète et Nutrition, Bron Cedex, France
| | - Mathilde Di Filippo
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Oullins Cedex, France; Hospices Civils de Lyon, Groupement Hospitalier Est, Service de Biochimie et Biologie Moléculaire Grand Est, Bron Cedex, France
| | - Sybil Charrière
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Oullins Cedex, France; Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'endocrinologie, Maladies Métaboliques, Diabète et Nutrition, Bron Cedex, France.
| |
Collapse
|
19
|
Marmontel O, Rollat-Farnier PA, Wozny AS, Charrière S, Vanhoye X, Simonet T, Chatron N, Collin-Chavagnac D, Nony S, Dumont S, Mahl M, Jacobs C, Janin A, Caussy C, Poinsot P, Tauveron I, Bardel C, Millat G, Peretti N, Moulin P, Marçais C, Di Filippo M. Development of a new expanded next-generation sequencing panel for genetic diseases involved in dyslipidemia. Clin Genet 2020; 98:589-594. [PMID: 33111339 DOI: 10.1111/cge.13832] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 08/12/2020] [Accepted: 08/13/2020] [Indexed: 12/12/2022]
Abstract
The aim of this study was to provide an efficient tool: reliable, able to increase the molecular diagnosis performance, to facilitate the detection of copy number variants (CNV), to assess genetic risk scores (wGRS) and to offer the opportunity to explore candidate genes. Custom SeqCap EZ libraries, NextSeq500 sequencing and a homemade pipeline enable the analysis of 311 dyslipidemia-related genes. In the training group (48 DNA from patients with a well-established molecular diagnosis), this next-generation sequencing (NGS) workflow showed an analytical sensitivity >99% (n = 532 variants) without any false negative including a partial deletion of one exon. In the prospective group, from 25 DNA from patients without prior molecular analyses, 18 rare variants were identified in the first intention panel genes, allowing the diagnosis of monogenic dyslipidemia in 11 patients. In six other patients, the analysis of minor genes and wGRS determination provided a hypothesis to explain the dyslipidemia. Remaining data from the whole NGS workflow identified four patients with potentially deleterious variants. This NGS process gives a major opportunity to accede to an enhanced understanding of the genetic of dyslipidemia by simultaneous assessment of multiple genetic determinants.
Collapse
Affiliation(s)
- Oriane Marmontel
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France.,Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Villeurbanne, France
| | | | - Anne-Sophie Wozny
- Service de Biochimie et Biologie Moléculaire Sud, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Sybil Charrière
- Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Villeurbanne, France.,Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE, Hospices Civils de Lyon, Bron Cedex, France
| | - Xavier Vanhoye
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France
| | - Thomas Simonet
- Cellule BioInformatique, Hospices Civils de Lyon, Bron Cedex, France
| | | | - Delphine Collin-Chavagnac
- Service de Biochimie et Biologie Moléculaire Sud, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Séverine Nony
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France
| | - Sabrina Dumont
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France
| | - Muriel Mahl
- Service de Biochimie et Biologie Moléculaire Sud, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Chantal Jacobs
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France
| | - Alexandre Janin
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France
| | - Cyrielle Caussy
- Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Villeurbanne, France.,Département Endocrinologie, Diabète et Nutrition, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France
| | - Pierre Poinsot
- Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE, Hospices Civils de Lyon, Bron Cedex, France
| | - Igor Tauveron
- Service d'endocrinologie, CHU G. Montpied, Clermont-Ferrand, France
| | - Claire Bardel
- Cellule BioInformatique, Hospices Civils de Lyon, Bron Cedex, France
| | - Gilles Millat
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France
| | - Noël Peretti
- Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Villeurbanne, France.,Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE, Hospices Civils de Lyon, Bron Cedex, France
| | - Philippe Moulin
- Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Villeurbanne, France.,Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE, Hospices Civils de Lyon, Bron Cedex, France
| | - Christophe Marçais
- Service de Biochimie et Biologie Moléculaire Sud, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Mathilde Di Filippo
- Service de Biochimie et Biologie moléculaire Grand Est, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, Bron Cedex, France.,Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Villeurbanne, France
| |
Collapse
|
20
|
Di Filippo M, Collardeau Frachon S, Janin A, Rajan S, Marmontel O, Decourt C, Rubio A, Nony S, Dumont S, Cuerq C, Charrière S, Moulin P, Lachaux A, Hussain MM, Bozon D, Peretti N. Normal serum ApoB48 and red cells vitamin E concentrations after supplementation in a novel compound heterozygous case of abetalipoproteinemia. Atherosclerosis 2019; 284:75-82. [PMID: 30875496 DOI: 10.1016/j.atherosclerosis.2019.02.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 02/16/2019] [Accepted: 02/19/2019] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND AIMS Abetalipoproteinemia (ABL) is a rare recessive monogenic disease due to MTTP (microsomal triglyceride transfer protein) mutations leading to the absence of plasma apoB-containing lipoproteins. Here we characterize a new ABL case with usual clinical phenotype, hypocholesterolemia, hypotriglyceridemia but normal serum apolipoprotein B48 (apoB48) and red blood cell vitamin E concentrations. METHODS Histology and MTP activity measurements were performed on intestinal biopsies. Mutations in MTTP were identified by Sanger sequencing, quantitative digital droplet and long-range PCR. Functional consequences of the variants were studied in vitro using a minigene splicing assay, measurement of MTP activity and apoB48 secretion. RESULTS Intestinal steatosis and the absence of measurable lipid transfer activity in intestinal protein extract supported the diagnosis of ABL. A novel MTTP c.1868G>T variant inherited from the patient's father was identified. This variant gives rise to three mRNA transcripts: one normally spliced, found at a low frequency in intestinal biopsy, carrying the p.(Arg623Leu) missense variant, producing in vitro 65% of normal MTP activity and apoB48 secretion, and two abnormally spliced transcripts resulting in a non-functional MTP protein. Digital droplet PCR and long-range sequencing revealed a previously described c.1067+1217_1141del allele inherited from the mother, removing exon 10. Thus, the patient is compound heterozygous for two dysfunctional MTTP alleles. The p.(Arg623Leu) variant may maintain residual secretion of apoB48. CONCLUSIONS Complex cases of primary dyslipidemia require the use of a cascade of different methodologies to establish the diagnosis in patients with non-classical biological phenotypes and provide better knowledge on the regulation of lipid metabolism.
Collapse
Affiliation(s)
- Mathilde Di Filippo
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France; INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France.
| | - Sophie Collardeau Frachon
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France; Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Institut de Pathologie, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Alexandre Janin
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France; Université de Lyon, Université Claude Bernard Lyon 1, Institut NeuroMyoGène, CNRS UMR5310, INSERM U1217, Lyon, F-69622, France.
| | - Sujith Rajan
- NYU Winthrop Hospital, 101 Mineola Blvd, Mineola, USA.
| | - Oriane Marmontel
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France; INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France.
| | - Charlotte Decourt
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Amandine Rubio
- Gastroentérologie et Nutrition Pédiatrique Hôpital Couple Enfant, CHU de Grenoble Alpes, Grenoble, F-38043, France; Laboratoire de Bioénergétique Fondamentale et Appliquée, INSERM U1055, Univ. Grenoble Alpes, F-38000, France.
| | - Séverine Nony
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Sabrina Dumont
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Charlotte Cuerq
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France; Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Sud, Service de Biochimie et Biologie Moléculaire, Hospices Civils de Lyon, Pierre, Benite cedex, F-69495, France.
| | - Sybil Charrière
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France; Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Philippe Moulin
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France; Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Alain Lachaux
- Service de Nutrition Pediatrique, Gastroenterologie and Hepatologie, Hôpital Femme Mère Enfants, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | | | - Dominique Bozon
- Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| | - Noël Peretti
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne F-69621, Oullins cedex, F-69921, France; Service de Nutrition Pediatrique, Gastroenterologie and Hepatologie, Hôpital Femme Mère Enfants, Hospices Civils de Lyon, Bron cedex, F-69677, France.
| |
Collapse
|
21
|
Serveaux Dancer M, Di Filippo M, Marmontel O, Valéro R, Piombo Rivarola MDC, Peretti N, Caussy C, Krempf M, Vergès B, Mahl M, Marçais C, Moulin P, Charrière S. New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia. J Clin Lipidol 2018; 12:1244-1252. [PMID: 30037590 DOI: 10.1016/j.jacl.2018.06.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 06/20/2018] [Accepted: 06/28/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND The LMF1 (lipase maturation factor 1) gene encodes a protein involved in lipoprotein lipase and hepatic lipase maturation. Homozygous mutations in LMF1 leading to severe hypertriglyceridemia (SHTG) are rare in the literature. A few additional rare LMF1 variants have been described with poor functional studies. OBJECTIVE The aim of this study was to assess the frequency of LMF1 variants in a cohort of 385 patients with SHTG, without homozygous or compound heterozygous deleterious mutations identified in lipoprotein lipase (LPL), apolipoprotein A5 (APOA5), apolipoprotein C2 (APOC2), glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) genes, and to determine their functionality. METHODS LMF1 coding variants were screened using denaturing high-performance liquid chromatography followed by direct sequencing. In silico studies of LMF1 variants were performed, followed by in vitro functional studies using human embryonic kidney 293T (HEK-293T) cells cotransfected with vectors encoding human LPL and LMF1 cDNA. LPL activity was measured in cell culture medium after heparin addition using human VLDL-TG as substrate. RESULTS Nineteen nonsynonymous coding LMF1 variants were identified in 65 patients; 10 variants were newly described in SHTG. In vitro, p.Gly172Arg, p.Arg354Trp, p.Arg364Gln, and p.Arg537Trp LMF1 variants decreased LPL activity, and the p.Trp464Ter variant completely abolished LPL activity. We identified a young girl heterozygote for the p.Trp464Ter variant and a homozygote carrier of the p.Gly172Arg variant with a near 50% decreased LPL activity in vitro and in vivo. CONCLUSION The study confirms the rarity of LMF1 variants in a large cohort of patients with SHTG. LMF1 variants are likely to be involved in multifactorial hyperchylomicronemia. Partial LMF1 defects could be associated with intermittent phenotype as described for p.Gly172Arg homozygous and p.Trp464Ter heterozygous carriers.
Collapse
Affiliation(s)
- Marine Serveaux Dancer
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, Pierre-Bénite, France
| | - Mathilde Di Filippo
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Service de Biochimie et Biologie moléculaire Grand Est, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | - Oriane Marmontel
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Service de Biochimie et Biologie moléculaire Grand Est, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | - René Valéro
- Université d'Aix-Marseille, C2VN, INSERM UMR1062, INRA UMR1260, APHM, service de nutrition, maladies métaboliques, endocrinologie Hôpital La Conception, Marseille, France
| | | | - Noël Peretti
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service d'Hépato-Gastroentérologie Nutrition pédiatrique, Bron, France
| | - Cyrielle Caussy
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'endocrinologie, diabète, nutrition, Centre Intégré de l'Obésité Rhône-Alpes, Fédération Hospitalo-Universitaire DO-iT, Lyon, Pierre-Bénite, France
| | - Michel Krempf
- CHU de Nantes, Hôpital de l'Hôtel Dieu, Service d'endocrinologie, maladies métaboliques et nutrition, Institut du thorax, Centre de Recherche en Nutrition Humaine, INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, Nantes, France
| | - Bruno Vergès
- CHU de Dijon, Service d'endocrinologie-diabétologie, INSERM LNC-UMR 1231, Dijon, France
| | - Murielle Mahl
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, Pierre-Bénite, France
| | - Christophe Marçais
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, Pierre-Bénite, France
| | - Philippe Moulin
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Bron, France
| | - Sybil Charrière
- INSERM U1060, Laboratoire Carmen, Université Lyon 1, INRA U1235, INSA de Lyon, CENS, Centre de Recherche en Nutrition Humaine Rhône Alpes, Villeurbanne, Oullins, France; Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, Bron, France.
| |
Collapse
|
22
|
Marmontel O, Charrière S, Simonet T, Bonnet V, Dumont S, Mahl M, Jacobs C, Nony S, Chabane K, Bozon D, Janin A, Peretti N, Lachaux A, Bardel C, Millat G, Moulin P, Marçais C, Di Filippo M. Single, short in-del, and copy number variations detection in monogenic dyslipidemia using a next-generation sequencing strategy. Clin Genet 2018; 94:132-140. [DOI: 10.1111/cge.13250] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Revised: 03/12/2018] [Accepted: 03/14/2018] [Indexed: 01/08/2023]
Affiliation(s)
- O. Marmontel
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
| | - S. Charrière
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE; Hospices Civils de Lyon; Bron France
| | - T. Simonet
- Service de Biostatistique-Bioinformatique; Hospices Civils de Lyon; Lyon France
- Univ Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR5558; Villeurbanne France
| | - V. Bonnet
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - S. Dumont
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - M. Mahl
- Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, GHS; Hospices Civils de Lyon; Pierre-Benite France
| | - C. Jacobs
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - S. Nony
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - K. Chabane
- Laboratoire d'hématologie, Biologie Moléculaire; Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon; Pierre-Benite France
| | - D. Bozon
- Plateforme NGS CHU Lyon, GHE; Hospices Civils de Lyon; Bron France
| | - A. Janin
- Plateforme NGS CHU Lyon, GHE; Hospices Civils de Lyon; Bron France
| | - N. Peretti
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE; Hospices Civils de Lyon; Bron France
| | - A. Lachaux
- Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE; Hospices Civils de Lyon; Bron France
- INSERM U 1111, Faculté de médecine Lyon Est; Université Lyon 1; Lyon France
| | - C. Bardel
- Service de Biostatistique-Bioinformatique; Hospices Civils de Lyon; Lyon France
- Univ Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR5558; Villeurbanne France
| | - G. Millat
- Plateforme NGS CHU Lyon, GHE; Hospices Civils de Lyon; Bron France
| | - P. Moulin
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE; Hospices Civils de Lyon; Bron France
| | - C. Marçais
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, GHS; Hospices Civils de Lyon; Pierre-Benite France
- CENS, Centre de Recherche en Nutrition Humaine Rhône-Alpes; Oullins France
| | - M. Di Filippo
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
| |
Collapse
|
23
|
Lassalle F, Marmontel O, Zawadzki C, Fretigny M, Bouvagnet P, Vinciguerra C. Recurrent F8
and F9
gene variants result from a founder effect in two large French haemophilia cohorts. Haemophilia 2018; 24:e213-e221. [DOI: 10.1111/hae.13480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2018] [Indexed: 12/29/2022]
Affiliation(s)
- F. Lassalle
- Centre de Biologie Pathologie; Laboratoire d'Hématologie; Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - O. Marmontel
- Département de Biochimie et Biologie Moléculaire; Centre de Biologie Pathologie Est; Groupe Hospitalier Est; Hospices Civils de Lyon; Bron France
| | - C. Zawadzki
- Centre de Biologie Pathologie; Laboratoire d'Hématologie; Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - M. Fretigny
- Centre de Biologie Pathologie Est; Service d'Hématologie Biologique; Groupe Hospitalier Est; Hospices Civils de Lyon; Bron France
| | - P. Bouvagnet
- Laboratoire de Cardiogénétique; Hospices Civils de Lyon; Université Lyon 1; Lyon France
| | - C. Vinciguerra
- Centre de Biologie Pathologie Est; Service d'Hématologie Biologique; Groupe Hospitalier Est; Hospices Civils de Lyon; Bron France
- Hémostase et Cancer; Université Lyon 1; Lyon France
| |
Collapse
|
24
|
Marmontel O, Di Filippo M, Marcais C, Nony S, Dumoux M, Dancer M, Caussy C, Charriere S, Moulin P. Strong heterogeneity in plasma triglyceride lipolysis in multifactorial chylomicronemia. Atherosclerosis 2017. [DOI: 10.1016/j.atherosclerosis.2017.06.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
25
|
Serveaux-Dancer M, Marçais C, Di Filippo M, Marmontel O, Moulin P, Charrière S. Coding variants identified in LMF1 gene in a cohort of hyperchylomicronemic patients. Atherosclerosis 2017. [DOI: 10.1016/j.atherosclerosis.2017.06.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Marmontel O, di Filippo M, Nony S, Marcais C, Caussy C, Charriere S, Sassolas A, Moulin P. Systematic assay of lipoprotein lipase activity and mass in cohort of patients with history of type V hyperlipidemia. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Marmontel O, di Filippo M, Galland M, Dumoux M, Marcais C, Villard A, Charriere S, Moulin P, Sassolas A. Variability of phenotypic expression in patients carriers of APOE gene mutations. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Di Filippo M, Marçais C, Charrière S, Marmontel O, Broyer M, Delay M, Merlin M, Nollace A, Valéro R, Lagarde M, Pruneta-Deloche V, Moulin P, Sassolas A. Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects. PLoS One 2014; 9:e99721. [PMID: 24886863 PMCID: PMC4041855 DOI: 10.1371/journal.pone.0099721] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Determination of lipoprotein lipase (LPL) activity is important for hyperchylomicronemia diagnosis, but remains both unreliable and cumbersome with current methods. Consequently by using human VLDL as substrate we developed a new LPL assay which does not require sonication, radioactive or fluorescent particles. METHODS Post-heparin plasma was added to the VLDL substrate prepared by ultracentrifugation of heat inactivated normolipidemic human serums, diluted in buffer, pH 8.15. Following incubation at 37°c, the NEFA (non esterified fatty acids) produced were assayed hourly for 4 hours. LPL activity was expressed as µmol/l/min after subtraction of hepatic lipase (HL) activity, obtained following LPL inhibition with NaCl 1.5 mmol/l. Molecular analysis of LPL, GPIHBP1, APOA5, APOC2, APOE genes was available for 62 patients. RESULTS Our method was reproducible (coefficient of variation (CV): intra-assay 5.6%, inter-assay 7.1%), and tightly correlated with the conventional radiolabelled triolein emulsion method (n = 26, r = 0.88). Normal values were established at 34.8 ± 12.8 µmol/l/min (mean ± SD) from 20 control subjects. LPL activities obtained from 71 patients with documented history of major hypertriglyceridemia showed a trimodal distribution. Among the 11 patients with a very low LPL activity (< 10 µmol/l/min), 5 were homozygous or compound heterozygous for LPL or GPIHBP1 deleterious mutations, 3 were compound heterozygous for APOA5 deleterious mutations and the p.S19W APOA5 susceptibility variant, and 2 were free of any mutations in the usual candidate genes. No homozygous gene alteration in LPL, GPIHBP1 and APOC2 genes was found in any of the patients with LPL activity > 10 µmol/l/min. CONCLUSION This new reproducible method is a valuable tool for routine diagnosis and reliably identifies LPL activity defects.
Collapse
|
29
|
Di Filippo M, Marçais C, Charrière S, Marmontel O, Broyer M, Delay M, Merlin M, Nollace A, Valéro R, Lagarde M, Pruneta-Deloche V, Moulin P, Sassolas A. Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects. PLoS One 2014; 9:e96482. [PMID: 24788417 PMCID: PMC4008628 DOI: 10.1371/journal.pone.0096482] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Accepted: 04/07/2014] [Indexed: 01/27/2023] Open
Abstract
Background Determination of lipoprotein lipase (LPL) activity is important for hyperchylomicronemia diagnosis, but remains both unreliable and cumbersome with current methods. Consequently by using human VLDL as substrate we developed a new LPL assay which does not require sonication, radioactive or fluorescent particles. Methods Post-heparin plasma was added to the VLDL substrate prepared by ultracentrifugation of heat inactivated normolipidemic human serums, diluted in buffer, pH 8.15. Following incubation at 37°c, the NEFA (non esterified fatty acids) produced were assayed hourly for 4 hours. LPL activity was expressed as µmol/l/min after subtraction of hepatic lipase (HL) activity, obtained following LPL inhibition with NaCl 1.5 mmol/l. Molecular analysis of LPL, GPIHBP1, APOA5, APOC2, APOE genes was available for 62 patients. Results Our method was reproducible (coefficient of variation (CV): intra-assay 5.6%, inter-assay 7.1%), and tightly correlated with the conventional radiolabelled triolein emulsion method (n = 26, r = 0.88). Normal values were established at 34.8±12.8 µmol/l/min (mean±SD) from 20 control subjects. LPL activities obtained from 71 patients with documented history of major hypertriglyceridemia showed a trimodal distribution. Among the 11 patients with a very low LPL activity (<10 µmol/l/min), 5 were homozygous or compound heterozygous for LPL or GPIHBP1 deleterious mutations, 3 were compound heterozygous for APOA5 deleterious mutations and the p.S19W APOA5 susceptibility variant, and 2 were free of any mutations in the usual candidate genes. No homozygous gene alteration in LPL, GPIHBP1 and APOC2 genes was found in any of the patients with LPL activity >10 µmol/l/min. Conclusion This new reproducible method is a valuable tool for routine diagnosis and reliably identifies LPL activity defects.
Collapse
Affiliation(s)
- Mathilde Di Filippo
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- * E-mail:
| | - Christophe Marçais
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- Laboratoire de Biochimie spécialisée, Centre de Biologie Sud, Centre Hospitalier Lyon-Sud, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Sybil Charrière
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- Fédération d′endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Oriane Marmontel
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
| | - Martine Broyer
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
| | - Mireille Delay
- Laboratoire de Biochimie spécialisée, Centre de Biologie Sud, Centre Hospitalier Lyon-Sud, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Micheline Merlin
- Laboratoire de Biochimie spécialisée, Centre de Biologie Sud, Centre Hospitalier Lyon-Sud, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Axel Nollace
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
| | - René Valéro
- Département de Nutrition, Maladies Métaboliques, Endocrinologie, APHM, Hôpital de la Timone, Aix-Marseille Université, UMR_S 1062, UMR_A1260, Marseille, France
| | - Michel Lagarde
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
| | - Valérie Pruneta-Deloche
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
| | - Philippe Moulin
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- Fédération d′endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Agnès Sassolas
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
| |
Collapse
|